ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "rheumatoid arthritis"

  • Abstract Number: 0079 • ACR Convergence 2024

    Characterization of the Tissue Resident Memorial T Cells in Autoimmune Arthritis: A Comparative Study of Psoriatic Arthritis and Rheumatoid Arthritis

    Siba Raychaudhuri1, Christine Abria2 and Smriti K Raychaudhuri3, 1UC Davis, School of Medicine/ VA Medical Center, Sacramento, Davis, CA, 2VA Medical Center Sacramento, Mather, CA, 3VA Sacramento Medical Center, Mather, CA

    Background/Purpose: Tissue-resident memory T cells (TRM) cells can drive localized, recurrent inflammation. TRM are site-specific T cells that take up long-term residence in peripheral tissues…
  • Abstract Number: 0187 • ACR Convergence 2024

    Impact of Sex on Medication Adherence in Members with Rheumatoid Arthritis, Psoriatic Arthritis, or Systemic Lupus Erythematosus

    Jean Park1, Cliff Rutter2, Elisea Avalos-Reyes3, Mary Anderson4, Will Cavers5, Dorothea Verbrugge6 and Kjel Johnson7, 1CVS Health, Hartford, CT, 2CVS Health, Fair Oaks Ranch, TX, 3CVS Health, Highland Village, TX, 4CVS Health, Irving, TX, 5CVS Health, Palm Beach Gardens, 6CVS Health, Salt Lake City, 7CVS Health, Tampa

    Background/Purpose: Factors influencing optimal medication adherence in members with rheumatoid arthritis (RA), psoriatic arthritis (PA), or systemic lupus erythematosus (SLE) are poorly understood. This evaluation…
  • Abstract Number: 0306 • ACR Convergence 2024

    Cardiovascular Risk Estimated with the New PREVENT Calculator and Disease Activity in Patients with Rheumatoid and Psoriatic Arthritis

    Aleydis Gonzalez Melendez1, Rebeca L. Polina-Lugo1, Maria F. Elizondo-Benitez2, Andrea Guajardo Aldaco1, Osvaldo Uresti3, Ricardo I. de la Rosa-Vazquez3, Iris Jazmín Colunga Pedraza1, Dionicio Galarza-Delgado4, jose Ramon Azpiri-Lopez5, Rosa Icela Arvizu-Rivera1 and Jesus Cardenas-de la Garza6, 1Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Mexico, 2Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Nuevo León, Mexico, 3Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Nuevo León, Mexico, 4UANL Hospital Universitario, Monterrey, Nuevo León, Mexico, 5Division of Cardiology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Mexico, 6Universidad Autónoma de Nuevo León, Monterrey, Nuevo León, Mexico

    Background/Purpose: The American Heart Association's PREVENT (Predicting Risk of Cardiovascular Disease EVENTs) is a new calculator developed in 2024, which estimates the 10- and 30-year…
  • Abstract Number: 0439 • ACR Convergence 2024

    Contraception Counseling and Contraception Use Among SLE and RA/JIA Patients at a Public Medical Center in Los Angeles: Investigating Teratogenic Medication Use and Language Preferences

    Laura Kobashigawa1, Cassidy Hernandez-Tamayo2, Katherine Ruddy3, Melissa Wilson2 and Leanna Wise4, 1University of Southern California/Los Angeles General Medical Center, Pasadena, CA, 2Keck School of Medicine of USC, Los Angeles, CA, 3University of Southern California/ Los Angeles General Medical Center, Los Angeles, CA, 4LAC+USC/Keck Medicine of USC, Pasadena, CA

    Background/Purpose: Systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA)/juvenile idiopathic arthritis (JIA) frequently impact women of reproductive age. Management of these patients is particularly important…
  • Abstract Number: 0470 • ACR Convergence 2024

    New Approach for Early and Accurate Diagnosis of Rheumatoid Arthritis-related Interstitial Lung Disease: Matrix Metalloproteinases 7 and 9 as Novel Blood Biomarkers

    Veronica Pulito-Cueto1, Belén Atienza-Mateo2, gonzalo Ocejo-Viñals3, Victor M. Mora-Cuesta4, David Iturbe-Fernández4, Joao Carlos Batista-Liz1, María Sebastián Mora-Gil5, Mónica Renuncio-García6, Elena González López3, José M. Cifrián7, Ricardo Blanco-Alonso8 and Raquel Lopez-mejias1, 1IDIVAL, Santander, Spain, 2Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Cantabria, Spain, 3Department of Immunology, Marqués de Valdecilla University Hospital (HUMV), Santander, Spain, 4Immunopathology Group, Valdecilla Research Institute (IDIVAL) and Department of Pneumology, Marqués de Valdecilla University Hospital (HUMV), Santander, 5Immunopathology Group, Valdecilla Research Institute (IDIVAL) and Department of Rheumatology, Marqués de Valdecilla University Hospital (HUMV), Santander, 6Division of Immunology, Hospital Universitario Marqués de Valdecilla, Immunopathology Group, IDIVAL, Santander, Spain, 7Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. Immunopathology group, IDIVAL, Santander, 8Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Spain

    Background/Purpose: Interstitial lung disease (ILD) is one of the main causes of death in rheumatoid arthritis (RA) patients [1]. Early diagnosis of RA-ILD+ is critical…
  • Abstract Number: 0487 • ACR Convergence 2024

    The Triglyceride to HDL Ratio, a Surrogate Marker of Insulin Resistance, Predicts All Cause and Cardiovascular Mortality in Rheumatoid Arthritis

    Jose Felix Restrepo Suarez1, Carlos Lorenzo1, Inmaculada Del rincon2 and Agustin Escalante1, 1UT Health San Antonio, San Antonio, TX, 2UT Health San Antonio, San Antonio

    Background/Purpose: The triglyceride to HDL cholesterol (TG/HDL) ratio, a recognized surrogate marker of insulin resistance, has emerged as a predictor of cardiovascular (CV) risk. However,…
  • Abstract Number: 0504 • ACR Convergence 2024

    Janus Kinase Inhibitors Persist Longer Than Biologics in Rheumatoid Arthritis: Retrospective Analysis of Real-world Outpatient Data from the German Rhadar Database

    Linus Maximilian Risser1, Torsten Witte2, Matthias Englbrecht3, Patrick-Pascal Strunz4, Matthias Froehlich5, Marc Schmalzing6, Michael Gernert7, Peter Bartz-Bazzanella8, Cay von Der Decken9, Kirsten Karberg10, Georg Gauler11, Susanna Spaethling-Mestekemper12, Christoph Kuhn13, Wolfgang Vorbrueggen14, Martin Welcker15 and Stefan Kleinert16, 1Hannover Medical School, Hannover, Germany, 2Dept of Immunology and Rheumatology, Hannover, Germany, 3Freelance Healthcare Data Scientist, Eckental, 4University hospital of Wuerzburg, Wuerzburg, Germany, 5Uniklinikum Wuerzburg, Medizinische Klinik II, Wuerzburg, Germany, 6University Hospital Wuerzburg, Würzburg, Germany, 7Medicine II, Division Rheumatology/Clinical Immunology, University Hospital of Wuerzburg, Wuerzburg, 8Rhein-Maas Klinikum, Wuerselen, Germany, 9Klinik für Internistische Rheumatologie, Rhein-Maas-Klinik Wuerselen, Würselen, 10Rheumatologisches Versorgungszentrum Steglitz, Berlin, Germany, 11rheumapraxis, Osnabrück, Germany, 12Rheumapraxis Muenchen, Muenchen, Germany, 13Praxis für Rheumatologie, Karlsruhe, Germany, 14Verein zur Foerderung der Rheumatologie e.V, Wuerselen, Germany, 15Medizinisches Versorgungszentrum für Rheumatologie Dr. M. Welcker GmbH, Planegg, Germany, 16Praxisgemeinschaft Rheumatologie - Nephrologie (PGRN), Erlangen, Germany

    Background/Purpose: Numerous biologic and targeted synthetic disease-modifying anti-rheumatic drugs (b/tsDMARDs) have been approved for treating rheumatoid arthritis (RA), including Janus kinase inhibitors (JAKi), rituximab, abatacept,…
  • Abstract Number: 0521 • ACR Convergence 2024

    Transcriptome Analysis of Drug Response in a Large Cohort of Immune-Mediated Inflammatory Disease Patients Supports Advanced Combination Therapy in Rheumatoid Arthritis

    Ernest Choy1, Maria López Lasanta2, Paloma Vela-Casasempere3, Antonio Fernandez Nebro4, Santos Castañeda5, Carlos Marras6, Jaime Calvo-Alén7, Jesus Tornero8, Juan Cañete9, Eugeni Domènech10, Javier Gisbert11, José Manuel Carrascosa12, Eduardo Fonseca13, Luis Bujanda14, Valle García15, Britta Siegmund16, Giampiero Girolomoni17, Holger Heyn18, Pere Santamaria19, Richard M Myers20, yolanda Guillen21, Sergio H Martínez-Mateu22, Sara Marsal23 and Antonio Julia24, and IMID Consortium, 1Cardiff University School of Medicine, Cardiff, United Kingdom, 2Hospital Universitari Vall d´Hebron, Rheumatology, Barcelona, Spain, 3Hospital General Universitario Alicante, Alicante, Spain, 4Hospital Regional Universitario Carlos Haya , Rheumatology, Málaga, Spain, 5Hospital Universitario de la Princesa, Madrid, Spain, 6Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Murcia, Spain, 7Department of Rheumatology, Hospital Araba, Vitoria, Pais Vasco, Spain, 8Hospital Universitario de Guadalajara, Guadalajara, Spain, 9Hospital Clinic an IDIBAPS, Barcelona, Spain, 10Hospital Universitari Germans Trias i Pujol, Barcelona, Spain, 11Hospital Universitario de la Princesa and IIS-IP, Madrid, Spain, 12Hospital Universitari Germans Trias i Pujol, Badalona, Spain, 13Complejo Hospitalario Universitario de A Coruña, A Coruña, Spain, 14Hospital Universitario de Donostia, San Sebastián, Spain, 15Hospital Universitario Reina Sofía, Córdoba, Spain, 16Charité – Universitätsmedizin Berlin, Berlin, Germany, 17University of Verona, Verona, Italy, 18Centre for Genomic Regulation (CNAG-CRG), National Centre for Genomic Analysis, Barcelona, Spain, 19Institut D'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain, 20HudsonAlpha Institute for Biotechnology, Huntsville, AL, 21Imidomics, Inc, Barcelona, Spain, 22IMIDOMICs, Barcelona, Spain, 23Vall Hebron Hospital Research Institute, Barcelona, Spain, 24Vall d'Hebron Hospital Research Institute, Barcelona, Spain

    Background/Purpose: Targeted therapies have failed to provide sustained disease remission in most patients suffering from immune-mediated inflammatory diseases (IMIDs). Combining existing drugs could overcome this…
  • Abstract Number: 0538 • ACR Convergence 2024

    Factors Associated with Upadacitinib Persistence and Risk Minimization Measures in Patients with Rheumatic Diseases in a Real-world Setting. UPAreal Study

    Alicia Garcia Dorta1, Cristina Rodríguez-Regalado2, Andrea Hernández-Martín3, Sonia Peña-Montelongo4, Cristina Martínez-González1, Elena Naveda-González5, Enrique González-Dávila6, Federico Diaz-González7 and Vanesa Hernández-Hernández8, 1Hospital Universitario de Canarias, San Cristobal de La Laguna, Spain, 2Hospital Universitario Ntra Sra de la Candelaria, Santa Cruz de Tenerife, Spain, 3Hospital Universitario de Gran Canaria Doctor Negrín, Las Palmas, Spain, 4Hospital Virgen de la Peña, Fuerteventura, Spain, 5Hospital Universitario Dr Negrín, Las Palmas de Gran Canaria, Spain, 6Departamento de Matemáticas, Estadística e Investigación Operativa, Universidad La Laguna, San Cristobal de La Laguna, Spain, 7Hospital Universitario de Canarias, La Laguna, Spain, 8Hospital Universitario de Canarias, San Cristobal de La Laguna, Canarias, Spain

    Background/Purpose: Upadacitinib (UPA), a Janus kinase inhibitor (JAKi) with three years of market experience, has not yet been the subject of a significant number of…
  • Abstract Number: 0869 • ACR Convergence 2024

    Deciphering Pathogenic Phenotypes by Multi-modal Deep Single-cell Blood Immunophenotyping in Individuals At-risk for Rheumatoid Arthritis

    Jun Inamo1, Joshua Keegan2, Alec Griffith2, Tusharkanti Ghosh1, Alice Horisberger2, Kaitlyn Howard2, John Pulford2, Ekaterina Murzin2, Brandon Hancock2, Thomas Eisenhaure3, Salina Dominguez4, Miranda Gurra5, Siddarth Gurajala3, Anna Helena Jonsson1, Jennifer Seifert6, Marie Feser7, Jill Norris8, Ye Cao2, William Apruzzese9, S. Louis Bridges10, Vivian Bykerk11, Susan Goodman12, Laura Donlin11, Gary S. Firestein13, Joan Bathon14, Laura B. Hughes15, Darren Tabechian16, Andrew Filer17, Costantino Pitzalis18, Jennifer Anolik19, Larry Moreland20, Nir Hacohen21, Joel Guthridge22, Judith James22, Carla Cuda5, Harris Perlman5, Michael B. Brenner2, Soumya Raychaudhuri23, Jeffrey Sparks24, Michael Holers7, Kevin Deane25, James A. Lederer26, Deepak Rao26 and Fan Zhang27, and the Accelerating Medicines Partnership RA/SLE Network, 1University of Colorado School of Medicine, Aurora, CO, 2Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 3Broad Institute of MIT and Harvard, Cambridge, 4Northwestern University, Chicago, 5Northwestern University, Chicago, IL, 6University of Colorado and Oklahoma Medical Research Foundation, Aurora, CO, 7Division of Rheumatology, University of Colorado School of Medicine, Aurora, CO, 8Colorado School of Public Health, Denver, CO, 9Accelerating Medicines Partnership® Program: Rheumatoid Arthritis and Systemic Lupus Erythematosus (AMP® RA/SLE) Network, Boston, MA, 10Division of Rheumatology, Weill Cornell Medical College, New York, NY, 11Hospital For Special Surgery, New York, NY, 12Hospital for Special Surgery, New York 10025, NY, 13University of California, San Diego, La Jolla, 14Columbia University, New York, NY, 15University of Alabama at Birmingham Medicine, Birmingham, AL, 16University of Rochester Medical Center, Rochester, 17Rheumatology Research Group, Institute for Inflammation and Ageing, NIHR Birmingham Biomedical Research Center and Clinical Research Facility, University of Birmingham, Birmingham, United Kingdom, 18QMUL, Bromley Kent, United Kingdom, 19University of Rochester Medical Center, Rochester, NY, 20University of Colorado, Denver, CO, 21Broad Institute of MIT and Harvard, Boston, MA, 22Oklahoma Medical Research Foundation, Oklahoma City, OK, 23Brigham and Women's Hospital, Boston, MA, 24Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA, Boston, MA, 25University of Colorado Denver Anschutz Medical Campus, Aurora, CO, 26Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 27University of Colorado, Aurora, CO

    Background/Purpose: Rheumatoid arthritis (RA) is a systemic autoimmune disease with currently no effective prevention strategies. Single-cell technologies have been recently used to investigate established RA…
  • Abstract Number: 0933 • ACR Convergence 2024

    NLRP3 Inflammasome Promotes Release of Peptidyl Arginine Deiminases2 and 4 from Human Neutrophils

    Teneema Kuriakose, Mingxin Yang, Lacie Scaletta and Gary Sims, Immunology Biosciences, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD

    Background/Purpose: Autoantibodies targeting citrullinated proteins (ACPAs) are a characteristic feature and a diagnostic marker in rheumatoid arthritis (RA). The generation of citrullinated protein autoantigens is…
  • Abstract Number: 0980 • ACR Convergence 2024

    Ambient Air Pollution and Initiation of bDMARDs in Newly Diagnosed Rheumatoid Arthritis: A Nested Case-Control Study of NIH All of Us Cohort

    Jiayi Zheng1, Nevena Barjaktarovic2 and Liangjing lu3, 1Washington University School of Medicine, St. Louis, MO, 2The Wright Center for Community Health, South Abington Township, PA, 3Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China (People's Republic)

    Background/Purpose: Ambient air pollution is a mixture of solid particles and gaseous pollutants derived from fossil fuel combustion and vehicle exhaust. Previous research has linked…
  • Abstract Number: 1037 • ACR Convergence 2024

    Recommendations for the Perioperative Use of DMARDs in Rheumatic Diseases: A Scoping Review

    Alice Terrett1, Athena Chin2, Mihye Kwon3, Samuel Whittle4 and Catherine Hill5, 1The Queen Elizabeth Hospital, Adelaide, Australia, 2Royal Adelaide Hospital, Tranmere, South Australia, Australia, 3Konyang University, College of Medicine, Daejeon, Republic of Korea, 4The Queen Elizabeth Hospital, Springfield, South Australia, Australia, 5The Queen Elizabeth Hospital, Woodville, South Australia, Australia

    Background/Purpose: The use of disease-modifying anti-rheumatic drugs (DMARDs) in the treatment of autoimmune rheumatic diseases, including rheumatoid arthritis (RA), has significantly improved disease and functional…
  • Abstract Number: 1246 • ACR Convergence 2024

    Long-Term Outcomes Based on the Sex of the Rheumatologist in a Prospective Cohort of RA Patients Receiving Biological Therapies

    Alessandro Giollo1, Mariangela Salvato2, Margherita Zen3 and doria Andrea4, 1Azienda Ospedale Università Padova, Padova, Padua, Italy, 2University of Padua, Padova, Italy, 3University of Padova, Padova, Padua, Italy, 4University of Padova, Padova, Italy

    Background/Purpose: To explore the influence of the rheumatologist's sex on long-term outcomes in patients with rheumatoid arthritis (RA) undergoing biologic therapy.Methods: This is a prospective,…
  • Abstract Number: 1336 • ACR Convergence 2024

    Risk of Malignancy Under the Treatments with Janus Kinase Inhibitors in Patients with Rheumatoid Arthritis: An Analysis Using Japanese Health Insurance Database

    Ryoko Sakai1, Eiichi Tanaka2, Eisuke Inoue3 and Masayoshi Harigai4, 1Meiji Pharmaceutical University, Tokyo, Japan, 2Division of Rheumatology, Department of Internal Medicine, Tokyo Women's Medical University School of Medicine, Tokyo, Japan, 3Showa University, Tokyo, Japan, 4Tokyo Women's Medical University, Tokyo, Japan

    Background/Purpose: Janus kinase inhibitors (JAKIs) have shown positive therapeutic impacts on treatments for rheumatoid arthritis (RA), whereas, there are concerns about the risk of malignancy…
  • « Previous Page
  • 1
  • …
  • 14
  • 15
  • 16
  • 17
  • 18
  • …
  • 188
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology